Holen Sie sich die Stockscreener-App
79.52
2.89%
-2.2718
Schlusskurs vom Vortag:
$81.79
Offen:
$81.71
24-Stunden-Volumen:
797.70K
Relative Volume:
0.33
Marktkapitalisierung:
$12.88B
Einnahmen:
$705.14M
Nettoeinkommen (Verlust:
$-453.90M
KGV:
-26.16
EPS:
-3.04
Netto-Cashflow:
$-551.29M
1W Leistung:
+4.06%
1M Leistung:
-1.12%
6M Leistung:
+87.42%
1J Leistung:
+130.50%
1-Tages-Spanne:
$79.34
$82.20
1-Wochen-Bereich:
$74.20
$82.20
52-Wochen-Spanne:
$23.95
$86.15
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Firmenname
Ionis Pharmaceuticals Inc
Sektor
Branche
Telefon
(760) 931-9200
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Vergleichen Sie IONS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
79.50 | 13.25B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.95 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.78 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.78 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Hochstufung | Goldman | Sell → Neutral |
| 2025-09-03 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Fortgesetzt | Jefferies | Buy |
| 2024-06-14 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Strong Buy |
| 2023-07-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-05-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2022-12-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-01 | Eingeleitet | Citigroup | Sell |
| 2022-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Hochstufung | UBS | Sell → Neutral |
| 2021-03-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Eingeleitet | UBS | Sell |
| 2020-12-15 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-02 | Eingeleitet | The Benchmark Company | Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Fortgesetzt | Goldman | Sell |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-08-09 | Bestätigt | Stifel | Hold |
| 2017-03-10 | Herabstufung | Goldman | Neutral → Sell |
| 2016-12-28 | Bestätigt | BMO Capital Markets | Outperform |
| 2016-12-27 | Bestätigt | Leerink Partners | Mkt Perform |
Alle ansehen
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema - Finviz
Ionis, Otsuka win EU nod for hereditary angioedema therapy - MSN
Massachusetts Financial Services Co. MA Increases Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Spinocerebellar Ataxias Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Amyloidosis Therapeutic Market to Worth Over US$ 6.37 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
Ionis, Otsuka win EU nod for hereditary angioedema drug (IONS) - Seeking Alpha
Ionis Pharmaceuticals (IONS) Gains EU Approval for Dawnzera - GuruFocus
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE) - Business Wire
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 12,922 Shares of Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $697,045.44 in Stock - MarketBeat
Eric Swayze Sells 9,884 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) EVP C Frank Bennett Sells 8,977 Shares - MarketBeat
Ionis Pharmaceuticals Executives Sell Shares - TradingView — Track All Markets
Ionis Pharmaceuticals Executives Engage in Stock Transactions - TradingView — Track All Markets
Big Picture: Is Ionis Pharmaceuticals Inc likely to announce a buyback2025 Pullback Review & Weekly Return Optimization Alerts - baoquankhu1.vn
Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth - Seeking Alpha
United States Transthyretin Amyloid Cardiomyopathy Market - openPR.com
Hereditary Angioedema Market Poised for Strong Growth, Valued - openPR.com
Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Shares Pass Above 200 Day Moving AverageShould You Sell? - MarketBeat
Spinal Muscular Atrophy Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme - Barchart.com
Insider Trends: Does Ionis Pharmaceuticals Inc have consistent dividend growthJuly 2025 Trade Ideas & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Revenue Check: Can Ionis Pharmaceuticals Inc scale operations efficiently2025 Institutional Moves & Low Risk High Reward Ideas - baoquankhu1.vn
JPM26: Tryngolza set to become first wholly owned Ionis blockbuster - Yahoo Finance
CEO Change: Can Ionis Pharmaceuticals Inc outperform in the next rally2025 Pullback Review & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Assessing Ionis Pharmaceuticals (IONS) Valuation After A Strong 1 Year Shareholder Return - Yahoo Finance
Trend Recap: Why retail investors favor Ionis Pharmaceuticals Inc. stockJuly 2025 Setups & Long-Term Capital Growth Strategies - Bộ Nội Vụ
How reliable is Ionis Pharmaceuticals Inc. (ISI) stock dividend growthSector Rotation Strategies & Free Unmatched Market Performance - bollywoodhelpline.com
Lobbying Update: $60,000 of IONIS PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts - marketscreener.com
Precision Trading with Ionis Pharmaceuticals Inc. (IONS) Risk Zones - Stock Traders Daily
Will Ionis Pharmaceuticals Inc. stock outperform international peersBull Run & Weekly Watchlist for Hot Stocks - ulpravda.ru
Ionis Pharmaceuticals EVP Devers sells $3.7m in shares By Investing.com - Investing.com Nigeria
Insider Sell Alert: Shannon Devers Sells 44,199 Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 44,199 Shares of Stock - MarketBeat
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates - sharewise.com
Ionis chalks up rare disease win with zilganersen - The Pharma Letter
How resilient is Ionis Pharmaceuticals Inc. stock in market downturns2025 Price Action Summary & Weekly Stock Breakout Alerts - Улправда
Will Ionis Pharmaceuticals Inc. (ISI) stock benefit from infrastructure billEarnings Recap Report & Accurate Buy Signal Alerts - Улправда
Momentum Shift: Will Ionis Pharmaceuticals Inc. stock gain from government policiesJuly 2025 Analyst Calls & Expert Verified Stock Movement Alerts - Улправда
Will Ionis Pharmaceuticals Inc. stock recover faster than peersEntry Point & Daily Risk Controlled Trade Plans - ulpravda.ru
Book value per share of Ionis Pharmaceuticals, Inc. – SWB:ISI - TradingView — Track All Markets
How Ionis Pharmaceuticals Inc. stock compares to industry benchmarksGap Down & Technical Pattern Based Buy Signals - ulpravda.ru
Can Ionis Pharmaceuticals Inc. stock sustain market leadershipTrade Entry Summary & Community Consensus Picks - Улправда
GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies - Nasdaq
Sentiment Review: Why Ionis Pharmaceuticals Inc. stock could see breakout soon - Улправда
Why Ionis Pharmaceuticals Inc. stock is a value investor pickTrade Exit Report & Risk Adjusted Buy/Sell Alerts - Улправда
Ionis Pharmaceuticals stock hits 52-week high at 83.62 USD By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals (IONS) Is Up 5.1% After Hepatitis B Drug Hits Phase 3 GoalsHas The Bull Case Changed? - Sahm
Why Ionis Pharmaceuticals (IONS) Is Up 5.1% After Hepatitis B Drug Hits Phase 3 Goals And What's Next - Yahoo Finance
Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):